BACKGROUND AND PURPOSE: CV following aneurysmal SAH is a significant cause of morbidity and mortality. We review our experiences using PTA and IA verapamil infusion for treating medically refractory cases. MATERIALS AND METHODS: We performed a retrospective review of patients with SAH admitted from July 2003 to January 2008. RESULTS: Of 546 patients admitted within 72 hours of symptom onset, 231 patients (42%) developed symptomatic CV and 189 patients (35%) required endovascular therapy. A total of 346 endovascular sessions were performed consisting of 1 single angioplasty, 286 IA verapamil infusions, and 59 combined treatments. PTA was performed on 151 vessel segments, and IA verapamil was infused in 720 vessel segments. IA verapamil doses ranged from 2.0 to 30.0 mg per vessel segment and from 3.0 to 55.0 mg per treatment session. Repeat treatments were necessary in 102 patients (54%) for persistent, recurrent, or worsening CV. There were 6 treatment-related complications, of which 2 resulted in clinical worsening. No deaths were attributable to endovascular therapy. At follow-up, 115 patients (61%) had a good outcome and 55 patients (29%) had a poor outcome. Sixteen patients died from causes related to SAH, while 3 died from other medical complications. CONCLUSIONS: Endovascular treatments are an integral part of managing patients with medically refractory CV. In our experience, PTA and IA verapamil are safe, with a low complication rate, but further studies are required to determine appropriate patient selection and treatment efficacy.
BACKGROUND AND PURPOSE: CV following aneurysmal SAH is a significant cause of morbidity and mortality. We review our experiences using PTA and IA verapamil infusion for treating medically refractory cases. MATERIALS AND METHODS: We performed a retrospective review of patients with SAH admitted from July 2003 to January 2008. RESULTS: Of 546 patients admitted within 72 hours of symptom onset, 231 patients (42%) developed symptomatic CV and 189 patients (35%) required endovascular therapy. A total of 346 endovascular sessions were performed consisting of 1 single angioplasty, 286 IA verapamil infusions, and 59 combined treatments. PTA was performed on 151 vessel segments, and IA verapamil was infused in 720 vessel segments. IA verapamil doses ranged from 2.0 to 30.0 mg per vessel segment and from 3.0 to 55.0 mg per treatment session. Repeat treatments were necessary in 102 patients (54%) for persistent, recurrent, or worsening CV. There were 6 treatment-related complications, of which 2 resulted in clinical worsening. No deaths were attributable to endovascular therapy. At follow-up, 115 patients (61%) had a good outcome and 55 patients (29%) had a poor outcome. Sixteen patients died from causes related to SAH, while 3 died from other medical complications. CONCLUSIONS: Endovascular treatments are an integral part of managing patients with medically refractory CV. In our experience, PTA and IA verapamil are safe, with a low complication rate, but further studies are required to determine appropriate patient selection and treatment efficacy.
Authors: Lei Feng; Brian-Fred Fitzsimmons; William L Young; Mitchell F Berman; Erwin Lin; Beverly D L Aagaard; Hoang Duong; John Pile-Spellman Journal: AJNR Am J Neuroradiol Date: 2002-09 Impact factor: 3.825
Authors: Wade S Smith; Christopher F Dowd; S Claiborne Johnston; Nerissa U Ko; Stephen J DeArmond; William P Dillon; Deepa Setty; Michael T Lawton; William L Young; Randall T Higashida; Van V Halbach Journal: Stroke Date: 2004-10-07 Impact factor: 7.914
Authors: Rod J Oskouian; Neil A Martin; Jae Hong Lee; Thomas C Glenn; Donald Guthrie; Nestor R Gonzalez; Arash Afari; Fernando Viñuela Journal: Neurosurgery Date: 2002-07 Impact factor: 4.654
Authors: Xiuyun Liu; Kais Gadhoumi; Ran Xiao; Nate Tran; Peter Smielewski; Marek Czosnyka; Steven W Hetts; Nerissa Ko; Xiao Hu Journal: Physiol Meas Date: 2019-01-23 Impact factor: 2.833
Authors: J M Ospel; C H Wright; R Jung; L L M Vidal; S Manjila; G Singh; D V Heck; A Ray; K A Blackham Journal: AJNR Am J Neuroradiol Date: 2019-12-26 Impact factor: 3.825
Authors: Parham Moftakhar; Prasheel Lillaney; Aaron D Losey; Daniel L Cooke; Alastair J Martin; Bradford R H Thorne; Ronald L Arenson; Maythem Saeed; Mark W Wilson; Steven W Hetts Journal: Radiology Date: 2015-06-01 Impact factor: 11.105
Authors: L Andereggen; J Beck; W J Z'Graggen; G Schroth; R H Andres; M Murek; M Haenggi; M Reinert; A Raabe; J Gralla Journal: AJNR Am J Neuroradiol Date: 2016-12-15 Impact factor: 3.825